CSL Ltd (ASX: CSL) Share Price and News

Ms Hewson is a former investment banker with over 35 years experience in the finance sector. She was previously an executive director of Schroders Australia Limited and has extensive financial markets, risk management and investment management expertise. She has long-term Non-Executive experience in a number of sectors bringing experience and insight on strategy, capital management and portfolio optimisation through cycles, financial and non-financial risk, social value, organisational culture and the changing external environment. In 2009, Ms Hewson was made an Officer of the Order of Australia for her services to the broader community and to business. She is a Director of Reserve Bank of Australia (since April 2021), Director of Infrastructure SA (since January 2019), Former Member of Federal Government Growth Centres Advisory Committee (from January 2015 to May 2021), Former Director of BHP Group Limited and BHP Group Plc (from March 2010 to November 2019) and Former Trustee Westpac Foundation (from May 2015 to May 2019). She is a Chair of the Corporate Governance Committee, Member of the Risk Management Committee and Member of the Human Resources Committee.

-

Dr McNamee has executive experience in the biopharmaceutical industry. Dr McNamee has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued a number of private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government's Financial System Inquiry. He is Chair of Geoff Ogilvy Foundation (since May 2021) and Former Chair of GenesisCare Limited (from July 2019 to June 2022). He is a Member of the Innovation and Development Committee, Corporate Governance Committee and Securities and Market Disclosure Committee.

Dr Cuthbertson has over 35 years experience in medical research and biotech development with biopharmaceutical companies and medical organisations. Prior to CSL, he was a senior scientist at Genentech Inc. Professor Cuthbertson spent five years doing molecular biology research as a staff member at the Howard Florey Institute in Melbourne, Australia and the National Institutes of Health in Maryland, US. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. He is a Member of the Council of the University of Melbourne (since January 2020), Director of the Grattan Institute (since January 2019) and Director of the Centre of Eye Research Australia (since March 2017). He is a Chair of the Innovation and Development Committee and Member of the Corporate Governance Committee.

Professor Maskell has international experience in science and commerce, with a focus in research, academia and entrepreneurship. Prior to this he was senior pro-vice-chancellor at the University of Cambridge in the UK and has also held roles at the University of Oxford, Imperial College London and Wellcome Biotech. Professor Maskell has experience across the private sector, reflecting his passion for the commercialisation of research initiatives. He has co-founded several biotech companies, including Arrow Therapeutics, which was sold to biopharmaceutical company AstraZeneca, and Discuva, which was sold to Summit Therapeutics. He has also served as a Non-Executive Director of Genus Plc, a FTSE 250 company. He is a a Director of the Grattan Institute (since November 2018), Vice-Chancellor of the University of Melbourne (since October 2018), Director of Melbourne Business School (since October 2018), Director of the Group of Eight Limited (since October 2018) and Director of Universities Australia Limited (since October 2018). He is a Member of the Innovation and Development Committee.

-

Dr Clark has executive and Non-Executive experience across a range of sectors, including scientific research, health, investment banking and financial services, education and mining. Through her roles, Dr Clark brings a global experience, with a focus on risk and proven health, safety and environment and technology performance. Dr Clark was chief executive of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) from 2009 until November 2014. Prior to joining CSIRO, she was a director at NM Rothschild and Sons (Australia) and held senior positions at BHP, including vice president (Technology) and vice president (Health, Safety and Environment). She is a Deputy Chancellor of Monash University (since January 2021), Chair of the Australian Space Agency Advisory Board (since January 2021), Member of the Global Advisory Council of the Bank of America Corporation (since December 2019), Director of Rio Tinto Limited and Rio Tinto Plc (since November 2014), Member of the Australian Advisory Board of the Bank of America (since July 2010), Former Head of the Australian Space Agency (from June 2018 to December 2020) and Care Australia Limited (from May 2015 to June 2020). She is a Chair of the Human Resources Committee, Member of the Corporate Governance Committee and Innovation and Development Committee.

Dr McKenzie has than 30 years of leadership experience in the global biotechnology industry, including managing complex organisations through compelling growth and transformation. Since joining CSL as COO in 2019, Prior to joining CSL, Dr McKenzie was Executive Vice President of Pharmaceutical Operations & Technology at Biogen. He also served in a range of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb and Merck.

-

-